Xeris Biopharma Holdings, Inc. — Form 8-K Summary
Business Context and Reporting Period
Xeris Biopharma Holdings, Inc. furnished a Form 8-K dated November 9, 2023, under Item 2.02 to announce results of operations and business highlights for the three and nine months ended September 30, 2023.
The filing identifies Exhibit 99.1 as a related press release dated November 9, 2023, but the press release content is not included in the provided filing text.
Financial Metrics
The provided filing text does not provide clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, or other financial metrics.
Material Changes Versus the Prior Comparable Period
The filing states that the accompanying press release contains quarterly results and business highlights, but the provided text does not describe specific changes versus the prior comparable periods.
Guidance, Outlook, Risks, and Unusual Items
The provided text does not include management guidance, outlook commentary, risk updates, contingencies, or unusual items. It only reports that such information may be contained in Exhibit 99.1.
Important Facts to Verify
- Obtain and review Exhibit 99.1 for the actual third-quarter and nine-month financial results.
- Verify revenue growth, product performance, operating expenses, profitability, and cash flow for the periods ended September 30, 2023.
- Review cash, debt, liquidity, financing activity, and management’s stated outlook.
- Confirm any business highlights, regulatory developments, litigation, contingencies, or other material events described in the press release.
- Note that the Item 2.02 information, including Exhibit 99.1, was furnished rather than filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference except where expressly stated.